Gossamer Bio (4GB) Price & Analysis

5 Followers

4GB Stock Chart & Stats

€0.20

€0.05(35.37%)

At close: Jul 28 4:00 PM EDT

€0.20

€0.05(35.37%)

Day’s Range― - ―

52-Week Range€0.11 - €3.17

Previous CloseN/A

Volume52.17K

Average Volume (3M)300.00

Market Cap

€65.48M

Enterprise Value€37.16

Total Cash (Recent Filing)€57.03M

Total Debt (Recent Filing)€39.10M

Price to Earnings (P/E)―

Beta-0.11

Next Earnings

Nov 05, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding488,846,700

10 Day Avg. Volume900

30 Day Avg. Volume300

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)-5.77

Price to Sales (P/S)14.62

P/FCF Ratio-4.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.92

Price Target Upside362.12% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)-0.24

Revenue Forecast (FY)€31.83M

Bulls Say, Bears Say

Bulls Say

Regulatory Path And Asset ControlGossamer regained worldwide seralutinib rights and control, while FDA feedback supports an NDA filing path. Retaining development and commercial authority could preserve long-term economics if regulatory and launch milestones are achieved.

Clinical And Mechanistic SupportConsistent secondary-endpoint performance and imaging evidence provide broader biological support beyond the primary result. These data may strengthen regulatory discussions and help differentiate seralutinib if confirmatory development succeeds.

Debt Maturity ExtensionThe exchange substantially reduces near-term refinancing pressure by moving most debt maturity to 2030. Greater maturity flexibility gives management more time to pursue the NDA and potential commercialization, although the restructuring has financing costs.

Bears Say

Severe Losses And Cash BurnThe company lacks durable operating profitability and continues to consume substantial cash relative to its modest revenue base. Persistent losses increase dependence on external capital and could constrain investment in development and commercialization.

Primary Endpoint Statistical ShortfallAlthough the primary measure was conventionally significant, it missed the study’s prespecified threshold. That weakens the evidentiary foundation for approval and leaves the program more dependent on secondary outcomes, mechanistic data and FDA discretion.

Short Runway And Shareholder DilutionLimited liquidity before potential approval creates ongoing financing risk, while the note exchange shifts value toward creditors through secured claims, shares and warrants. Further capital needs could dilute existing holders and limit strategic flexibility.

Gossamer Bio News

Gossamer Bio announces upt to $250M structured private placement

Gossamer Bio (GOSS) entered into a securities purchase agreement with certain new and existing institutional investors for a...

5h ago

GOSS

Gossamer Bio reports Q2 EPS (8c), consensus (12c)

Cash, cash equivalents and marketable securities totaled $57.0 million as of June 30, 2026. Gossamer expects the combination...

5d ago

GOSS

Gossamer Bio price target lowered to $4 from $15 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Gossamer Bio (GOSS) to $4 from $15...

5d ago

GOSS

Gossamer Bio upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Gossamer Bio (GOSS) to Outperform from Market Perform with an unchanged $1 price target after the...

25d ago

GOSS

Morning Movers: Ensign Group surges following second quarter results

Stock futures are sharply higher Monday as investors return from the weekend encouraged by easing geopolitical tensions and...

25d ago

AMR

AZN

Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights

Gossamer Bio (GOSS) announced a series of regulatory, strategic, and corporate updates. Following a productive Pre-NDA Type B...

25d ago

GOSS

Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal

Gossamer Bio ( ($GOSS) ) has shared an announcement. On August 20, 2026, Gossamer Bio entered into a...

5h ago

GOSS

GOSS Earnings this Week: How Will it Perform?

Gossamer Bio (GOSS) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street analysts...

12d ago

GOSS

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($OTLK) ), ( ($HBAN) ), ( ($CORT) ), ( ($CAPR)...

20d ago

CAPR

CORT

Gossamer Bio Reclaims Seralutinib Rights and Control

Gossamer Bio ( ($GOSS) ) has issued an announcement. On July 23, 2026, Gossamer Bio terminated its collaboration...

25d ago

GOSS

Gossamer Bio Sets Conversion Terms for Convertible Notes

Gossamer Bio ( ($GOSS) ) has provided an update. On July 1, 2026, Gossamer Bio announced the initial...

2M ago

GOSS

Gossamer Bio announces determination of conversion rate for senior secured notes

Gossamer Bio (GOSS) announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes...

2M ago

GOSS

Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Gossamer Bio (GOSS) to $2 from $5 and keeps a...

2M ago

GOSS

Gossamer Bio Announces Final Convertible Notes Exchange Results

The latest update is out from Gossamer Bio ( ($GOSS) ). On June 17, 2026, Gossamer Bio announced...

2M ago

GOSS

4GB FAQ

What was Gossamer Bio Inc’s price range in the past 12 months?

Gossamer Bio Inc lowest stock price was €0.11 and its highest was €3.17 in the past 12 months.

What is Gossamer Bio Inc’s market cap?

Gossamer Bio Inc’s market cap is €65.48M.

When is Gossamer Bio Inc’s upcoming earnings report date?

Gossamer Bio Inc’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.

How were Gossamer Bio Inc’s earnings last quarter?

Gossamer Bio Inc released its earnings results on Aug 13, 2026. The company reported -€0.069 earnings per share for the quarter, beating the consensus estimate of -€0.106 by €0.037.

Is Gossamer Bio Inc overvalued?

According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gossamer Bio Inc pay dividends?

Gossamer Bio Inc does not currently pay dividends.

What is Gossamer Bio Inc’s EPS estimate?

Gossamer Bio Inc’s EPS estimate is -0.04.

How many shares outstanding does Gossamer Bio Inc have?

Gossamer Bio Inc has 488,846,700 shares outstanding.

What happened to Gossamer Bio Inc’s price movement after its last earnings report?

Gossamer Bio Inc reported an EPS of -€0.069 in its last earnings report, beating expectations of -€0.106. Following the earnings report the stock price went down -4%.

Which hedge fund is a major shareholder of Gossamer Bio Inc?

Currently, no hedge funds are holding shares in DE:4GB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gossamer Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-68.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio (4GB) Earnings & Revenues

Historic Earnings Reports

4GB Company Deck

4GB Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all DE:4GB earnings summaries

4GB Stock 12 Month Forecast

Average Price Target

€0.92

▲(362.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.72754088,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.9242343708,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.2418557232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.27227237538461535,0.3935447507692308,0.5148171261538461,0.6360895015384616,0.757361876923077,0.8786342523076923,0.9999066276923076,1.121179003076923,1.2424513784615385,1.363723753846154,1.4849961292307692,1.6062685046153846,{"y":1.72754088,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.2104795669846154,0.26995913396923077,0.3294387009538462,0.3889182679384615,0.44839783492307694,0.5078774019076924,0.5673569688923077,0.6268365358769231,0.6863161028615385,0.7457956698461539,0.8052752368307693,0.8647548038153847,{"y":0.9242343708,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.1579889017846154,0.16497780356923078,0.17196670535384614,0.17895560713846154,0.18594450892307693,0.19293341070769232,0.19992231249230769,0.20691121427692308,0.21390011606153847,0.22088901784615386,0.22787791963076925,0.23486682141538462,{"y":0.2418557232,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.704,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.054,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.028,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.724,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.901,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.332,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.274,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.291,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.146,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.151,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >